Romiplostim — Discount Pricing

Other medications in Blood Disorders

• Sargramostim
• Tranexamic Acid
• Voxelotor
• Aminocaproic Acid
• Avatrombopag
• Crizanlizumab
• Darbepoetin
• Desmopressin IV

What Romiplostim is approved for (FDA label)

Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding.

Source: Read the full FDA label on DailyMed. Label effective date: June 23, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Romiplostim (FDA label)

For injection: 125 mcg, 250 mcg or 500 mcg of Nplate as a sterile, lyophilized, solid white powder in single-dose vials. For injection: 125 mcg, 250 mcg or 500 mcg of romiplostim as a lyophilized powder in single-dose vials. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: c45f9a58-37c1-4f76-8e36-97d38c577037. SPL document ID: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Romiplostim (FDA label)

The following clinically significant adverse reactions are discussed in greater detail in other sections: Progression of Myelodysplastic Syndromes [see Warnings and Precautions ( 5.1 )] Thrombotic/Thromboembolic Complications [see Warnings and Precautions ( 5.2 )] Loss of Response to Nplate [see Warnings and Precautions ( 5.3 )] In adult patients, the most common adverse reactions (≥ 5% higher patient incidence in Nplate versus placebo) are arthralgia, dizziness, insomnia, myalgia, pain in extremity, abdominal pain, shoulder pain, dyspepsia, and paresthesia.

Source: FDA prescribing information (DailyMed). Set ID: c45f9a58-37c1-4f76-8e36-97d38c577037. SPL document ID: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Romiplostim (FDA label)

None. None ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: c45f9a58-37c1-4f76-8e36-97d38c577037. SPL document ID: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Romiplostim (FDA label)

In some patients with MDS, Nplate increases blast cell counts and increases the risk of progression to acute myelogenous leukemia. ( 5.1 ) Thrombotic/thromboembolic complications have resulted from increases in platelet counts with Nplate use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate. ( 5.2 ) Severe thrombocytopenia may persist during Nplate treatment due to neutralizing antibodies or other causes. ( 5.3 ) 5.1 Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia Progression from myelodysplastic syndromes (MDS) to acute myelogenous leukemia (AML) has been observed in adult clinical trials with Nplate. A randomized, double-blind, placebo-controlled trial enrolling adult patients with severe thrombocytopenia and International Prognostic Scoring System (IPSS) low or intermediate-1 risk MDS was terminated due to more cases of AML observed in the Nplate arm. This trial consisted of a 58-week study period with a 5-year long-term follow-up phase.

Source: FDA prescribing information (DailyMed). Set ID: c45f9a58-37c1-4f76-8e36-97d38c577037. SPL document ID: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Romiplostim (FDA label)

Nplate may be used with other medical ITP therapies, such as corticosteroids, danazol, azathioprine, intravenous immunoglobulin (IVIG), and anti-D immunoglobulin [see Clinical Studies ( 14.1 )] .

Source: FDA prescribing information (DailyMed). Set ID: c45f9a58-37c1-4f76-8e36-97d38c577037. SPL document ID: 7f47b815-d08b-46fe-aee9-d2cef6e86ec0. Label effective date: June 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.